Articles written by Todos Medical - Benzinga

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

5-day and 30-day dosing regimen for 60-pill bottle allows for both support (5-day dosing) to reduce 3CL protease levels and to maintain (30-day dosing) low 3CL protease levels

Partner Content

Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022

Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022

New York, NY, and Tel Aviv, ISRAEL – April 27, 2022 - Todos Medical, Ltd.

Partner Content

Todos Medical To Present At The Emerging Growth Conference

Todos Medical To Present At The Emerging Growth Conference

- Wednesday, April 27, 2022 at 10:00am – 10:45am EST -

Partner Content

Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics

Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics

Strengthens Management Team and Positions the Company for Growth and Expansion

Partner Content

Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study

Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study

New York, NY, and Tel Aviv, ISRAEL – April 20, 2022 - Todos Medical, Ltd.

Partner Content

Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group

Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group

New York, NY, and Tel Aviv, ISRAEL – April 19, 2022 - Todos Medical, Ltd.

Partner Content

Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label

Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label

New York, NY, and Tel Aviv, ISRAEL – April 6, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd.

Partner Content

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

New York, NY, and Tel Aviv, ISRAEL – April 4, 2022 - Todos Medical, Ltd.

Partner Content

UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates

UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates

New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd.

Partner Content

Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates

Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates

New York, NY, and Tel Aviv, ISRAEL – April 1, 2022 - Todos Medical, Ltd.

Partner Content

Todos Medical Reports Case Study Of Patient With Long COVID

Todos Medical Reports Case Study Of Patient With Long COVID

New York, NY, and Tel Aviv, ISRAEL, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd.

Partner Content

Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products

Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products

New York, NY, and Tel Aviv, ISRAEL – March 27, 2022 - Todos Medical, Ltd.

Partner Content

Todos Medical To Present At The Proactive One2One Virtual Forum

Todos Medical To Present At The Proactive One2One Virtual Forum

- Thursday, March 17, 2022 at 2:00PM – 2:30PM ET -

Partner Content

Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma

Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma

- Forms new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir™, Tollovid®, Tollovid Daily™ and TolloTest™ for COVID-19 -

Partner Content

Todos Medical To Present At The Emerging Growth Conference

Todos Medical To Present At The Emerging Growth Conference

- Wednesday, March 16, 2022 at 1:30 pm – 2 pm EST -

Partner Content

Todos Medical Appoints Greg Meiselbach As Vice President Of Government Affairs

Todos Medical Appoints Greg Meiselbach As Vice President Of Government Affairs

New York, NY, and Tel Aviv, ISRAEL – March 8, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company,

Partner Content

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

Phase 2 Study NLC-V-01 closed early after interim data analysis due to positive clinical efficacy

Partner Content

Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

Clinical Data will be released Thursday, January 27th, 2022

Partner Content

PEPPERDINE UNIVERSITY HOSTS THE 22ND ANNUAL CELEBRITY FLAG FOOTBALL CHALLENGE®, PRESENTED BY TODOS MEDICAL'S TOLLOVID®

PEPPERDINE UNIVERSITY HOSTS THE 22ND ANNUAL CELEBRITY FLAG FOOTBALL CHALLENGE®, PRESENTED BY TODOS MEDICAL'S TOLLOVID®

In support of First Responders, Military Service Members and Boys and Girls Youth Groups

Partner Content

Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

New York, NY, and Tel Aviv, ISRAEL – January 18, 2022 - Todos Medical, Ltd.

Partner Content